A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

GSK Investigational Site, Vienna

GSK Investigational Site, Madrid

GSK Investigational Site, Majadahonda (Madrid)

GSK Investigational Site, Hanover

GSK Investigational Site, Seville

GSK Investigational Site, Monterrey NL

GSK Investigational Site, Homburg

GSK Investigational Site, Heidelberg

GSK Investigational Site, Zrifin

GSK Investigational Site, Ashkelon

GSK Investigational Site, Regensburg

GSK Investigational Site, Würzburg

GSK Investigational Site, Beijing

GSK Investigational Site, Beijing

GSK Investigational Site, Beijing

GSK Investigational Site, Shanghai

GSK Investigational Site, Wuhan

GSK Investigational Site, Tomsk

GSK Investigational Site, Kemerovo

GSK Investigational Site, Xi'an

GSK Investigational Site, Boston

GSK Investigational Site, Dallas

GSK Investigational Site, Rosario

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Corrientes

GSK Investigational Site, Santa Fe

GSK Investigational Site, Graz

GSK Investigational Site, Innsbruck

GSK Investigational Site, Edmonton

GSK Investigational Site, London

GSK Investigational Site, Prague

GSK Investigational Site, Dresden

GSK Investigational Site, Leipzig

GSK Investigational Site, Aichi

GSK Investigational Site, Fukuoka

GSK Investigational Site, Hokkaido

GSK Investigational Site, Hyōgo

GSK Investigational Site, Miyagi

GSK Investigational Site, Tochigi

GSK Investigational Site, Tokyo

GSK Investigational Site, Tokyo

GSK Investigational Site, Amsterdam

GSK Investigational Site, Riyadh

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Barcelona

GSK Investigational Site, Cambridge

GSK Investigational Site, Clydebank

GSK Investigational Site, London